Skip to main content

Investigating the effects of two novel 4-MMPB analogs as potent lipoxygenase inhibitors for prostate cancer treatment



Lipoxygenases are one of the critical signaling mediators which can be targeted for human prostate cancer (PC) therapy. In this study, 4-methyl-2-(4-methylpiperazinyl)pyrimido[4,5-b]benzothiazine (4-MMPB) and its two analogs, 4-propyl-2-(4-methylpiperazinyl)pyrimido[4,5-b]benzothiazine (4-PMPB) and 4-ethyl-2-(4-methylpiperazinyl)pyrimido[4,5-b]benzothiazine (4-EMPB), were proposed to have anti-tumor properties in prostate cancer.


After synthesizing the compounds, cytotoxic effects of 4-MMPB and its two analogs against PC-3 cancerous and HDF normal cells were investigated by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay and then mechanism of cell death was assessed by flow cytometry. Finally, the anti-tumor effects of the mentioned compounds were investigated in an immunocompromised C57BL/6 mouse model.


4-PMPB and 4-EMPB had similar anti-cancer effects on PC-3 cells as compared with 4-MMPB, while they were not effective on normal cells. Moreover, apoptosis and ferroptosis were the main mechanisms of induced cell death in these cancerous cells. Furthermore, in vivo results indicated that both analogs had similar anti-cancer effects as 4-MMPB, leading to delayed tumor growth without any noticeable side effects in weight loss and histological investigations.


Thus, our results suggest that specific targeting of lipoxygenases via 4-MMPB analogs can be considered as a treatment of choice for PC therapy, although it requires further investigations.


Cancer is considered as a serious concern affecting the health of all human societies. Prostate cancer (PC) is the most common malignancy in males worldwide, representing the second leading cause of mortality [1]. Various environmental factors such as lifestyle, physical activity, obesity and dietary habits, particularly high intake of saturated fats, have been related to an increased risk of PC [2]. Arachidonic acid (AA), one of the most important polyunsaturated fatty acids (PUFAs), constitutes an essential part of our diet and is found in meat, egg and dairy products [3]. This important fatty acid is required to maintain normal physiological functions, including tissue regeneration, cell membrane fluidity [4] and immune response [5]. However, excessive consumption of this fatty acid has an important role in cancer development [6] and this link has been established in numerous studies [7, 8]. For example, experiments on mouse models supported the effects of high-fat diet (HFD) in development and progression of prostate cancer [9, 10]. Moreover, it has been demonstrated that HFD results in increased tumor weight and number of intestinal polyps in mice [11, 12]. Similar effects have been reported in mouse models with breast cancer [13, 14].

Human lipoxygenases (LOXs) are a family of non-heme iron based enzymes that are involved in the metabolism of AA and other PUFAs into biologically active metabolites [15]. So far, several human LOX isoforms including 15-LOX-1, 15-LOX-2, 5-LOX and 12-LOX have been identified and categorized based on enzymatic characterization [16]. For example, 15-LOXs introduce the oxygen at carbon 15 of AA backbone. Two distinct human 15-LOXs are widely distributed in various tissues, exhibiting different substrate preferences. 15-LOX-1, one of the critical enzymes of mammalian LOX family, is physiologically overexpressed in specific cancerous tissues such as prostate [17] and renal cancer [18], while it is poorly expressed in colorectal [19, 20], lung [21], esophageal [22] and bladder cancers [23] as well as chronic myeloid leukemia [24]. Thus, 15-LOX-1 is involved in both tumor promotion and suppression depending on the type of cancer. This enzyme predominantly metabolizes linoleic acid (LA) to 13S-hydroperoxyoctadecadienoic acid (13S-HpODE), but also metabolizes AA to 12S- and 15S-hydroperoxyeicosatetraenoic acid (15S-HpETE) [25]. 15-LOX-2 is constitutively expressed in healthy normal prostate tissue [17] while it is down regulated in prostate [26], lung [27] and esophageal cancers [28]. In contrast to 15-LOX-1, 15-LOX-2 preferentially catalyzes AA to 15S-HpETEs and poorly metabolizes LA [29]. Similarly, 5-LOX and 12-LOX utilize AA to synthesize 5S-HpETE and 12S-HpETE, respectively [30, 31] and their expression is linked to PC spreading and metastasis [32]. In this context, blocking overexpressed LOX enzymes in PC could be one of the promising targets facilitating drug discovery and treatment. There are several studies reporting different compounds with significant inhibitory effects on 15-LOX-1. Coumarin-based inhibitors, such as 8-farnesyloxycoumarin [33], 5-farnesyloxycoumarin [34] and 7-farnesyloxycoumarin [35] exhibited inhibitory potency against 15-LOX-1 with half maximal inhibitory concentration (IC50) values of 2.64, 8.32 and 11.8 µM, respectively. Furthermore, the inhibitory activities of stylosin and its derivatives have also been shown on soybean LOX-1 [36]. These compounds exerted their anti-cancer effects in PC cells via induction of apoptosis. In addition, indole-based inhibitors, such as 14d [37], indolylpyrazoline (4b) [38] and 9c (i472) [39] are members of another group of potent 15-LOX-1 inhibitors. Sarveswaran et al. [40], treated PC cells with MK591 as a specific chemical inhibitor of 5-LOX activity in order to induce apoptosis via down-regulation of protein kinase C-epsilon (PKCε) and disruption of c-Myc signaling [41]. Moreover, it has been shown that inhibition of 12-LOX activity markedly sensitizes PC cells to radiation both in vivo and in vitro [42, 43]. Recent studies have demonstrated that ferroptotic pathway as another type of programmed cell death can be mediated via LOXs in some contexts to eradicate cancers [44, 45].

Considering the association between lipoxygenase activity and PC development, the inhibition of these pathways provides an interesting therapeutic strategy to suppress tumorigenesis and malignant growth. It has been shown that 4-methyl-2-(4 methylpiperazinyl)pyrimido[4,5-b]benzothiazine (4-MMPB) as a heterocyclic compound, functions as an effective and specific 15-lipoxygenase inhibitor with an IC50 value of 18 µM [46]. Moreover, its analog, 4-propyl-2-(4-methylpiperazinyl)pyrimido[4,5-b]benzothiazine (4-PMPB), exhibited robust inhibitory potency against soybean LOX-1 with an IC50 value of 9 µM [47]. In this study, inhibitory potency of the other analog with ethyl moiety at position 4 of pyrimido benzothiazine (4-ethyl-2-(4-methylpiperazinyl)pyrimido[4,5-b]benzothiazine (4-EMPB)) against lipoxygenases was also investigated (Table 1). We aimed to test the anti-cancer effects of 4-PMPB and 4-EMPB on PC cells both in vitro and in vivo. Cytotoxicity and anti-cancer properties of the three compounds were evaluated on cancerous (human prostate cancer cell line; PC-3) and normal (human dermal fibroblast; HDF) cells. Moreover, the mechanism of cell death was assessed via FITC-annexin V and propidium iodide (PI) staining. Tumor inhibitory effects of the compounds were then evaluated in immunocompromised C57BL/6 mice bearing human PC-3 cells.

Table 1 Chemical characteristics of 4-MMPB and its analogs


All chemical reagents and solvents were purchased from Merck (Darmstadt, Germany) and used as received without further purification. 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide (MTT) and trypsin–EDTA were purchased from Tinab Shimi (Mashhad, Iran). Roswell Park Memorial Institute 1640 (RPMI 1640) culture medium and Dulbecco’s modified Eagle’s medium (DMEM) were bought from Gibco (Scotland, UK). Fetal bovine serum (FBS; Schwalbach, Germany), and penicillin–streptomycin were obtained from Gibco (Loughborough, UK). Soybean LOX-1 (L1; type I-B; EC 1,13,11,12) and linoleic acid (L1376) were bought from Sigma‐Aldrich (St. Louis, USA). Itraconazole and co-amoxiclav were purchased from Tehran Darou Pharmaceutical Co. and AFA Chemi, Pharmaceutical Co. (Tehran, Iran), respectively.

Synthesis of compounds

4-MMPB and 4-PMPB were synthesized as previously described [46, 47]. The new analog 4-EMPB was similarly synthesized via the following procedure (as illustrated in Fig. 1).

Fig. 1

Synthetic pathway of 4-EMPB

2-[(5-Bromo-2-chloro-6-ethylpyrimidin-4-yl)sulfanyl]aniline (2)

To a solution of 5-bromo-2,4-dichloro-6-ethylpyrimidine 1 (CAS No. 1373331–48-6) (2.54 g, 10 mmol) and triethylamine (1.2 g) in chloroform (30 ml), 2-aminothiophenol (1.25 g, 10 mmol) was added dropwise with vigorous stirring over a minute. Solvent was removed and the residue was washed with warm water and then crystallized from ethanol (2.6 g, 83% yield, Melting Point: 153 °C (dec). IR: 3300, 3432 cm−1, 1H NMR (CDCl3): 1.27 (t, 3H, CH3), 2.87 (q, 2H, CH2), 4.30 (broad, 2H, NH2), 6.77–7.43 (m, 4H), 13C NMR (CDCl3): 14.1, 29.8, 114.4, 117.5, 118.5, 120.4, 128.0, 128.7, 147.3, 157.4, 161.5, 162.8).

4-ethyl-2-(4-methylpiperazinyl)pyrimido[4,5-b]benzothiazine (4-EMPB) (4)

A mixture of 2-[(5-bromo-2-chloro-6-ethylpyrimidin-4-yl)sulfanyl]aniline 2 (3.43 g, 10 mmol) and 4-methylpiperazin (30 mmol) in ethanol (20 ml) was heated under reflux for 5 h. Water (40 ml) was added to the solution and separated sticky liquid (intermediate 3) was dried at 80 °C for an hour and immediately utilized without purification. Sodium amide (1.2 g, 30 mmol) was added to stirred solution of the intermediate 3 in acetonitrile (30 ml), and then heated under reflux condition (3 h). The solvent was removed and a solution of 2% acetic acid (20 ml) was added to the residue and filtered. Then the residue was crystallized from benzene to give 4-ethyl-2-(4-methylpiperazinyl)pyrimido[4,5-b]benzothiazine (4-EMPB) (4) as a yellow powder (55% yield). Melting Point: 171–173 °C; IR: 3348 cm−1, 1H NMR: (CDCl3) 1.26 (t, 3H, CH3), 2.34 (m, 7H, CH3N(CH2)2), 2.86 (t, 2H, CH2), 3.73 (t, 4H, 2(CH2N)), 6.92 (dd, 2H, C7H & C8H), 7.35 (d, 1H, C6H), 8.20–8.42 (d, 2H, C9H & NH); 13C NMR: (CDCl3) 14.1, 23.9, 39.5, 44.1, 46.7, 56.4, 94.7, 120.5, 122.7, 124.1, 131.1, 136.7, 141, 155.6, 159.6, 167.0; Elemental analysis of C17H21N5S: Calculated: C, 62.36; H, 6.46; N, 21.39; S, 9.79. Found: C, 62.41; H, 6.49; N, 21.27; S, 9.72.

Enzyme inhibitory assessment

Linoleic acid and two assay solutions (A and B) were prepared in advance. Solution A was 50 mM 3-(dimethylamino)benzoic acid (DMAB) in l00 mM phosphate buffer (pH 7.0). Solution B was a mixture of l0 mM 3-methyl-2-benzothiazolinonehydrazone hydrochloride (MBTH; 3 ml), and hemoglobin (5 mg ml−1, 3 ml) in 50 mM phosphate buffer at pH 5.0 (25 ml). A linoleic acid solution was prepared by mixing 5.6 mg linoleic acid with 0.5 ml methanol and then diluted with 100 mM KOH to a final volume of 5 ml (4 mM). In the assay, a solution of inhibitors in dimethyl sulfoxide (DMSO) (12.5 μl), soybean LOX-1 (4000 units ml−1 in 50 mM phosphate buffer pH 7.0; 25 μl), and phosphate buffer, pH 7.0 (50 mM; 435 μl) were mixed in 48-well plates, and pre incubation was carried out for 10 min at 30 °C. A control test was performed with the same volume of DMSO. After the pre incubation, linoleic acid solution (25 μl) was added to start the peroxidation reaction at 30 °C, and 10 min later, solution A (135 μl) and then solution B (65 μl) were added to start the color formation. After 3 min, 100 μl of a 2% sodium dodecyl sulphate (SDS) solution was added to terminate the reaction. The absorbance at 598 nm was compared with the control. These experiments were performed in triplicate and the data were analyzed using GraphPad Prism 6.0 (San Diego, USA).

Preparing different solutions of compounds for cell culture

Two mg of each compound was dissolved in 100 μl hydrochloric acid (HCl 0.3 N) to make a primary stock solution. Different concentrations (1.56–50 μg ml−1) were then prepared by serial dilution from the primary stock solution and further diluted in the culture medium. Moreover, culture medium containing 0.25% HCl 0.3 N was used as a negative control in all experiments for a better evaluation.

Cell culture

PC-3 cells were obtained from Pasteur Institute (Tehran, Iran) and routinely cultured in RPMI 1640 supplemented with 10% FBS. In order to investigate the toxicity of the compounds on normal cells, in vitro experiments were also performed on HDF cells. These cells were kindly provided by Academic Center for Education, Culture and Research (ACECR, Mashhad, Iran) and grown in DMEM supplemented with 10% FBS. Both cell lines were kept at 37 °C containing 5% CO2 in a humidified incubator.

Cytotoxicity assay

The MTT reduction assay is a standard quantitative method to evaluate cytotoxicity. This assay measures cellular dehydrogenases, and is considered as an easy, safe and highly reproducible method. Viable cells reduce yellow tetrazolium salt to purple formazan crystals and thus the color change serves as a marker reflecting cell viability [48].

PC-3 and HDF cells were seeded in 96-well plates (NEST, China) at a density of 6000 and 8000 cells per well, respectively and incubated at 37 °C with 5% CO2. Next day, the media were changed and both cell lines were treated with various concentrations (1.56–50 μg ml−1) of the compounds and cisplatin. Experiments were carried out in triplicate for 4-PMPB, 4-EMPB and 4-MMPB as well as cisplatin as a positive control. After 24, 48 and 72 h of treatments, 20 μl MTT solution (5 mg ml−1 in PBS; phosphate buffered saline) was added to each well, and cells were incubated in the dark for 3–4 h. The media were then removed and purple crystals were dissolved in 160 μl DMSO. The absorbance in each well was measured at 540 nm as reference wavelength in an enzyme-linked immunosorbent assay (ELISA) reader (Awareness Technology, USA) and relative optical density (OD) values were recorded. The percentage of viable cells was calculated using the following equation [49]:

$${\text{Cell viability }}\left( \% \right) = {1}00 \times \left[ {\left( {{\text{OD}}_{{{\text{mean}}}} {\text{of treated cells}} - {\text{OD}}_{{{\text{mean}}}} {\text{blank}}} \right)/\left( {{\text{OD}}_{{{\text{mean}}}} {\text{of negative control cells }}\left( {{\text{HCl}}0.{\text{3 N}}} \right) - {\text{OD}}_{{{\text{mean}}}} {\text{blank}}} \right)} \right].$$

Flow cytometric analysis

To determine the mechanism of cell death induced by 4-MMPB analogs, flow cytometry was employed using the Annexin V-FITC kit with PI (BioLegend, San Diego, USA) according to the manufacturer’s instructions. We performed co-treatment experiments with the compounds and a ferroptosis inhibitor (IC50 values of 4-PMPB + , 4-EMPB + , and 4-MMPB + deferoxamine (80 µM)) on PC-3 cells, to distinguish between ferroptosis and apoptosis mechanisms [50]. In order to evaluate the apoptosis mechanism, cells were treated with the ½ × IC50 and IC50 values of 4-PMPB, 4-EMPB, 4-MMPB, and cisplatin for 24 h. Then the cells were collected by trypsinization (0.25% trypsin-1 mM EDTA), washed twice with PBS, followed by centrifugation, and resuspended in a binding buffer. Samples were stained with Annexin V-FITC/ PI followed by 15 min incubation at room temperature. Finally, cells were subjected to flow cytometry (BD Accuri C6, San Jose, USA) and the data were analyzed by FlowJo 7.6.1 software (Ashland, USA). Moreover, PC-3 cells treated with 0.3 N HCl were used as a control to eliminate the effects of solvent.

Anti-cancer evaluation of compounds on a PC-3 xenograft tumor model

The animal experiments were approved and conducted in accordance with Animal Ethics Committee of Ferdowsi University of Mashhad (FUM) (IR.UM.REC.1399.001). C57BL/6 mice were inbred in an animal house at FUM and maintained under pathogen-free conditions. Immunosuppression of male C57BL/6 mice (4–6 weeks old) was carried out according to the protocol described by Jivrajani et al. [51]. However, in this study, for immunosuppression ketoconazole and ampoxin drugs were replaced with itraconazole and co-amoxiclav. After completion of this procedure, the total white blood cell (WBC) and lymphocyte counts were evaluated to confirm the immunosuppression protocol.

The PC-3 tumor model was generated by subcutaneous injection of 3 × 106 cells in 100 μl RPMI 1640 into the right flank of the immunocompromised mice. When the tumor volume reached 100–200 mm3, the animals were randomly divided into 9 groups (n = 8 per group) and treated with: 1) PBS as a negative control; 2) HCl (0.3 N) as solvent control; 3) 4-PMPB (10 mg kg−1); 4) 4-PMPB (50 mg kg−1); 5) 4-EMPB (10 mg kg−1); 6) 4-EMPB (50 mg kg−1); 7) 4-MMPB (10 mg kg−1); 8) 4-MMPB (50 mg kg−1) and 9) cisplatin as a positive control (2 mg kg−1). The changes in tumor size and body weight were monitored every other day. The tumor volumes were calculated using the following formula [52]:

$${\text{Tumor volume }}\left( {{\text{mm}}^{{3}} } \right) = \left( {\text{Tumor length}} \right) \times \left( {\text{Tumor width}} \right)^{{2}} \times 0.{5}$$

To validate the anti-tumor activity in different experimental groups, mice were sacrificed 15 days post treatment. Meanwhile, blood samples were collected and histological analyses were also performed to investigate the possible side effects. Hematological analyses were performed in an automated hematology analyzer (Sysmex XP-300; Lincolnshire, USA). The tissue slices were stained with hematoxylin and eosin (H&E) and observed by an optical microscope (Olympus IX70; Tokyo, Japan).

Statistical analysis

All statistical analyses were carried out using GraphPad Prism software 6.0 (San Diego, USA). First the Kolmogorov–Smirnov test was performed to evaluate the normal distribution of the data. Then, differences between groups were assessed with Student’s t-test (group pairs) or one-way ANOVA (multiple groups) followed by Tukey multiple comparison tests. Experiments were performed in triplicate and data are presented as mean ± standard error or standard deviation as required. p-values < 0.05 were considered as significant.


Enzyme activity assay

Lipoxygenase inhibitory activity of 4-MMPB and its analogs was assessed on soybean LOX-1 and the inhibitory potencies (IC50 values) of the mentioned compounds were calculated from their sigmoidal dose–response curves (Fig. 2). As expected, 4-EMPB decreased lipoxygenase activity by IC50 value of 14.3 μM, which falls between inhibitory potencies of 4-PMPB (IC50 = 8.6 μM) and 4-MMPB (IC50 = 17.1 μM).

Fig. 2

Dose–response curves for soybean LOX-1 inhibition by 4-MMPB and its analogs. Data are expressed as mean ± SEM, n = 3

In vitro cell viability assay

In present study, we first evaluated in vitro cytotoxicity and anti-cancer properties of 4-PMPB and 4-EMPB on PC-3 and HDF cells, and the results were compared with 4-MMPB as a potent 15-lipoxygenase inhibitor and cisplatin as a well-known chemotherapeutic drug. After exposing both cell lines to different concentrations of compounds, cell viability was determined by MTT assay and IC50 values were calculated. The IC50 values and dose–response curves are presented in Table 2 and Fig. 3, respectively. Dose–response curves indicated that 4-PMPB and 4-EMPB have similar anti-cancer effects on PC-3 cells as compared with 4-MMPB. As shown in Table 2, 4-PMPB, showed no obvious cytotoxicity on normal cells, while, 4-EMPB and 4-MMPB exhibited a weak cytotoxicity on HDF cells. Furthermore, cisplatin showed prominent cytotoxic effects on both prostate cancer and normal cells.

Table 2 Anti-proliferative activity of tested compounds on PC-3 and HDF cells during 24, 48, and 72 h of treatments
Fig. 3

Dose–response curves of different compounds on PC-3 and HDF cells as evaluated by MTT assay. Cells were treated with 4-PMPB, 4-EMPB, 4-MMPB and cisplatin for 24, 48, and 72 h. Data are expressed as mean ± SEM, n = 3

Evaluating the mechanism of cell death

To evaluate the mechanism of cell death, PC-3 cells co-treated with 4-PMPB, 4-EMPB, or 4-MMPB in combination with deferoxamine, a ferroptosis inhibitor, were assessed using Annexin V-FITC/ PI staining and compared with those treated with the compounds only. The results revealed that the population in Q2 (Annexin V positive/PI positive) was markedly decreased after co-treatment with deferoxamine as compared to those evaluated in the absence of this ferroptosis inhibitor. These observations suggest that 4-MMPB and its two analogs have probably induced both apoptosis and ferroptosis in PC-3 cells (Fig. 4). Flow cytometry–based quantification showed the percentage of early and late apoptotic/ ferroptotic cells (Q3+Q2) increased from 0.133% in control to 52.38%, 60.9%, 41.5% and 67.8% in 4-PMPB-, 4-EMPB-, 4-MMPB-, and cisplatin- treated PC-3 cells, respectively, when treated with IC50 values of the compounds.

Fig. 4

Flow cytometric analysis of cell death induced in PC-3 cells treated with deferoxamine, \(\frac{1}{2}\)× IC50 and IC50 values of each compound after 24 h. a Untreated, b 0.3 N HCl, c deferoxamine (80 µM), d 4-PMPB + deferoxamine (122.303 + 80 µM), e 4-EMPB + deferoxamine (107.44 + 80 µM), f 4-MMPB + deferoxamine (100.76 + 80 µM), g 4-PMPB (61.15 µM), h 4-PMPB (122.303 µM), i 4-EMPB (53.72 µM), j 4-EMPB (107.44 µM), k 4-MMPB (50.38 µM), l 4-MMPB (100.76 µM) and m cisplatin

In vivo anti-tumor effects of the compounds

After administration of immunosuppression protocol, blood samples were collected and their parameters were compared with normal C57BL/6 mice. Significant reduction in WBC, lymphocyte, and neutrophil counts (p < 0.0001) was confirmed in immunocompromised mice (Fig. 5). On day 11 after immunosuppression, PC-3 cells were injected subcutaneously. Immunocompromised mice bearing PC-3 tumors were then treated with PBS, 0.3 N HCl, 4-PMPB (10 and 50 mg kg−1), 4-EMPB (10 and 50 mg kg−1), 4-MMPB (10 and 50 mg kg−1), and cisplatin, and then their body weights and tumor volumes were measured every other day. As shown in Fig. 6a–c, tumor growth was effectively inhibited after treatment with high doses of 4-PMPB, 4-EMPB, and 4-MMPB. In contrast, tumors in control groups receiving PBS and 0.3 N HCl grew markedly during the 15 days follow up period. Furthermore, the positive control group, receiving cisplatin, exhibited a significant decrease in tumor growth as compared with the controls and other experimental groups with lower doses. The results revealed that, there was no significant difference between tested compounds (4-PMPB, 4-EMPB) and 4-MMPB in tumor inhibition.

Fig. 5

Effects of immunosuppression protocol on white blood cell (WBC), lymphocyte and neutrophil counts. Significant differences were observed between control and immunosuppression groups. Data are expressed as mean ± SD, n = 3, **** p < 0.0001

Fig. 6

In vivo therapeutic efficacy of 4-PMPB, 4-EMPB and 4-MMPB on immunocompromised C57BL/6 mice bearing PC-3 tumors. a Representative image of tumors at day 15 after various treatments. b Tumor growth curves indicated, cisplatin and high doses of 4-PMPB, 4-EMPB and 4-MMPB had remarkable anti-tumor effects during the 15 days of treatments. c At the end of the experiment, tumor volumes were measured and significant differences were observed between the PBS and HCl controls and those treated with 50 mg kg-1 of the compounds as well as cisplatin groups. d The body weights of different groups were continuously evaluated during the 15 days follow up. e There was a significant difference in body weight loss between cisplatin and other treatment groups on day 15. Data are expressed as mean ± SD, n = 8. ** p < 0.01, *** p < 0.001 and **** p < 0.0001

In vivo side effects evaluation

The side effects of the compounds were evaluated by measuring the body weights, hematological analyses, and H & E staining of different organs. Body weights of various groups were compared and as shown in Fig. 6d and e, the cisplatin treated group demonstrated the lowest body weights, which were significantly lower than other experimental groups (p < 0.01). However, no significant changes in body weights were observed between 4-PMPB- (10 and 50 mg kg−1), 4-EMPB- (10 and 50 mg kg−1) and 4-MMPB- (10 and 50 mg kg−1) treated groups.

To determine possible side effects of various treatments in vivo, biochemical parameters such as urea, aspartate transaminase (AST) and alanine aminotransferase (ALT) were evaluated in different experimental groups (Fig. 7). Urea levels did not change in all treatment groups as compared with the immunosuppressed group. Mice treated with 4-PMPB, 4-EMPB and 4-MMPB at concentrations of 50 mg kg−1 had significantly elevated AST and ALT levels compared with immunosuppressed control group. Similarly, the group treated with cisplatin had significantly increased serum liver enzymes compared to control group (p < 0.0001). Histological analysis showed no obvious tissue damages in major organs including liver, kidney, and spleen, following 4-PMPB, 4-EMPB, and 4-MMPB treatments. However, mild and local accumulation of inflammatory cells was noticed in cisplatin treated group (Fig. 8). Meanwhile, the tumor tissue treated with cisplatin and high doses of compounds exhibited a higher degree of cell death than the other experimental groups (Fig. 9). Apoptosis of tumor cells with nuclear and cytoplasmic condensation and also tumor necrosis were visualized in treated groups. However, further immunohistochemical analyses are required to confirm the exact type of cell death in tumor tissues.

Fig. 7

Effects of different treatments on serum biochemical parameters including a urea, b aspartate transaminase (AST) and c alanine aminotransferase (ALT). Data are expressed as mean ± SD, n = 3, ** p < 0.01, *** p < 0.001 and **** p < 0.0001

Fig. 8

Hematoxylin and eosin (H&E)-stained images of major organs (liver, kidney, and spleen) collected on day 15 after treatments. Mild and local accumulation of inflammatory cells was noticed in cisplatin treated group (black arrows). Scale bar: 200 μm

Fig. 9

Hematoxylin and eosin (H & E)-stained images of tumor tissues upon different experimental conditions: a PBS, b 0.3 N HCl, c 4-PMPB (10 mg kg−1), d 4-PMPB (50 mg kg−1), e 4-EMPB (10 mg kg−1), f 4-EMPB (50 mg kg−1), g 4-MMPB (10 mg kg−1), h 4-MMPB (50 mg kg−1) and i cisplatin. Black arrows and “N” represent mitotic figures and necrotic areas, respectively within the tumor mass. Scale bar: 200 μm


In recent years, cancer incidence rate has increased significantly especially in developing countries and discovering more effective treatments has emerged as a major concern. Chemotherapy is one of the conventional treatment modalities, which can increase patient’s survival. However, therapeutic index can be decreased due to serious limitations of chemotherapy including drug resistance, poor specificity, and undesirable, long term side effects [53, 54]. Discovering cell signaling molecules which can trigger an apoptotic pathway in cancerous cells is crucial to improve therapeutic outcomes. Lipoxygenases are considered as a family of important signaling mediators that their overexpression is associated with tumor initiation and progression of prostate cancer [55]. Development of effective lipoxygenase inhibitors may successfully diminish cell proliferation in the tumor mass. An example of established 15-lipoxygenase inhibitors is 4-MMPB [46], which has been well documented in recent studies on PC-3 cells [33,34,35,36]. In this study, two 4-MMPB analogs, 4-PMPB and 4-EMPB, with inhibitory effects on lipoxygenase activity [46, 47] were employed and 4-PMPB indicated the most selective anti-proliferative effects as compared with the other two. The significantly lower cytotoxicity of these compounds on HDF cells can be attributed to the low expression of lipoxygenases in these normal cells [56, 57]. Considering the lower levels of cell death population after co-treatment with 4-PMPB, 4-EMPB or 4-MMPB compounds and deferoxamine, compared with those treated with the compounds only, it is proposed that cell death is triggered through both apoptosis and ferroptosis pathways. It has been shown that ALOX15 expression is regulated by a mutant form of P53 and results in promoting PC [58]. Moreover, 13S-HODE, the major metabolite of 15-LOX-1 can interact with anti-apoptotic mediators such as B-cell lymphoma 2 (BCL2) and insulin-like growth factor receptor-1 (IGF-1R) which leads to inhibition of apoptotic signaling pathways in PC [59,60,61]. Additionally, recent studies demonstrated that 15-LOX-1 is one of the fundamental regulators in ferroptosis pathway [44, 62], and is involved in PUFA oxidation and pro‐ferroptotic lipid peroxide generation [63]. In order to better evaluate the efficacy of anti-cancer agents, treatment strategy should also be assessed in animal experimental models [64, 65]. Nude and immunocompromised mice models are commonly used as hosts for human cancer cell lines. However, nude mice bear several drawbacks due to high cost, low tumorigenesis rate, high sensitivity, difficult maintenance and high mortality rate [66]; therefore we used immunocompromised mice bearing human PC as a preferred model. There are a number of immunosuppressive medications such as glucocorticoids, azathioprine, cyclophosphamide, methotrexate, cyclosporine, ketoconazole and tacrolimus which are used alone or in combination to prevent human tumor xenografts rejection in murine models [64]. Cunha et al. [67] reported xenotransplantation of human glioblastoma cells in rats by cyclosporine treatment (5 mg per kg per day) until the end of experiments. Similarly, Du et al. [68] reported use of cyclosporine treatment (10 mg per kg per day) for development of human hepatocarcinoma cells xenograft in a C57BL/6 mouse model. Moreover, Rose et al. [69] reported that xenologous skin transplantation in an immunosuppressed sheep model was made possible by using cyclosporine (2–3 mg kg−1) in combination with ketoconazole (10 mg kg−1) after 18 days. In present study, human PC xenograft was developed according to the Jivrajani’s protocol in C57BL/6 mice [51]. Blood count analysis after administration of immunosuppression protocol, and tumor growth volume in control groups confirmed successful immunosuppression and xenotransplantation in mouse model. Moreover, in vivo results demonstrated that while cisplatin treatment led to a significant decrease in tumor size, it suffered from side effects including a significant decrease in body weight. Furthermore, the highest dose of 4-PMPB and 4-EMPB (50 mgkg−1) possessed similar anti-cancer effects as compared with 4-MMPB, leading to delayed tumor growth without noticeable side effects in weight loss and histological assessments.


Targeted therapeutic strategies such as lipoxygenase inhibition in PC can reduce tumor growth and help in improving clinical outcomes. Data generated from our study showed that, use of 4-PMPB and 4-EMPB can be considered as a treatment of choice to trigger both apoptosis and ferroptosis pathways and inhibit PC cell survival in vitro and in vivo probably via specific targeting of lipoxygenases. For this purpose, different approaches can be recommended, and use of nanotechnology-based drug delivery systems (DDSs) is one of the most attractive strategies. In this regard, mentioned compound inhibitors of lipoxygenases can be encapsulated into specific nanocarriers such as liposomes, which would enable us to use them in clinical trials. Moreover, surface of nanocarriers can be decorated with specific ligands referred as active targeting, to reduce possible side effects on normal tissues and facilitate their availability to tumor microenvironment.







13-Hydroperoxyoctadecadienoic acid


13-Hydroxyoctadecadienoic acid


Hydroperoxyeicosatetraenoic acid


Hydroxyeicosatetraenoic acid










Arachidonic acid


Dulbecco’s modified Eagle’s medium


Dimethyl sulfoxide


Fetal bovine serum


Hematoxylin & Eosin


Hydrochloric acid


Human dermal fibroblast

IC50 :

Half maximal inhibitory concentration


Insulin-like growth factor-1


3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide


Standard deviation


  1. 1.

    Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med. 2018;8:a030361.

    PubMed  PubMed Central  Article  Google Scholar 

  2. 2.

    Robles LA, Wright SJ, Hackshaw-McGeagh L, Shingler E, Shiridzinomwa C, Lane JA, Martin RM, Burden S. Prostate cancer survivors’ preferences on the delivery of diet and lifestyle advice: a pilot best-worst discrete choice experiment. Pilot Feasibility Stud. 2020;6:1–9.

    Article  Google Scholar 

  3. 3.

    Sokoła-Wysoczańska E, Wysoczański T, Wagner J, Czyż K, Bodkowski R, Lochyński S, Patkowska-Sokoła B. Polyunsaturated fatty acids and their potential therapeutic role in cardiovascular system disorders—a review. Nutrients. 2018;10:1561.

    PubMed Central  Article  CAS  PubMed  Google Scholar 

  4. 4.

    Tallima H, El Ridi R. Arachidonic acid: physiological roles and potential health benefits—a review. J Adv Res. 2018;11:33–41.

    CAS  PubMed  Article  Google Scholar 

  5. 5.

    Radzikowska U, Rinaldi AO, Çelebi Sözener Z, Karaguzel D, Wojcik M, Cypryk K, Akdis M, Akdis CA, Sokolowska M. The influence of dietary fatty acids on immune responses. Nutrients. 2019;11:2990.

    CAS  PubMed Central  Article  PubMed  Google Scholar 

  6. 6.

    Long J, Zhang C-J, Zhu N, Du K, Yin Y-F, Tan X, Liao DF, Qin L. Lipid metabolism and carcinogenesis, cancer development. Am J Cancer Res. 2018;8:778–91.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Fleshner N, Bagnell PS, Klotz L, Venkateswaran V. Dietary fat and prostate cancer. J Urol. 2004;171:S19–24.

    CAS  PubMed  Google Scholar 

  8. 8.

    Williams CD, Whitley BM, Hoyo C, Grant DJ, Iraggi JD, Newman KA, Gerber L, Taylor LA, McKeever MG, Freedland SJ. A high ratio of dietary n-6/n-3 polyunsaturated fatty acids is associated with increased risk of prostate cancer. Nutr Res. 2011;31:1–8.

    CAS  PubMed  Article  Google Scholar 

  9. 9.

    Cho HJ, Kwon GT, Park H, Song H, Lee KW, Kim J-I, Park JH. A high-fat diet containing lard accelerates prostate cancer progression and reduces survival rate in mice: possible contribution of adipose tissue-derived cytokines. Nutrients. 2015;7:2539–61.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  10. 10.

    Hu MB, Xu H, Zhu WH, Bai PD, Hu JM, Yang T, Jiang HW, Ding Q. High-fat diet-induced adipokine and cytokine alterations promote the progression of prostate cancer in vivo and in vitro. Oncol Lett. 2018;15:1607–15.

    PubMed  Google Scholar 

  11. 11.

    Day SD, Enos RT, McClellan JL, Steiner J, Velázquez KT, Murphy E. Linking inflammation to tumorigenesis in a mouse model of high-fat-diet-enhanced colon cancer. Cytokine. 2013;64:454–62.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  12. 12.

    O’Neill AM, Burrington CM, Gillaspie EA, Lynch DT, Horsman MJ, Greene MW. High-fat Western diet–induced obesity contributes to increased tumor growth in mouse models of human colon cancer. Nutr Res. 2016;36:1325–34.

    CAS  PubMed  Article  Google Scholar 

  13. 13.

    Mustafi D, Fernandez S, Markiewicz E, Fan X, Zamora M, Mueller J, Brady MJ, Conzen SD, Karczmar GS. MRI reveals increased tumorigenesis following high fat feeding in a mouse model of triple-negative breast cancer. NMR Biomed. 2017;30:e3758.

    Article  CAS  Google Scholar 

  14. 14.

    Zhu Y, Aupperlee MD, Haslam SZ, Schwartz RC. Pubertally initiated high-fat diet promotes mammary tumorigenesis in obesity-prone FVB mice similarly to obesity-resistant BALB/c mice. Transl Oncol. 2017;10:928–35.

    PubMed  PubMed Central  Article  Google Scholar 

  15. 15.

    Nie D. Cyclooxygenases and lipoxygenases in prostate and breast cancers. Front Biosci. 2007;12:1574–85.

    CAS  PubMed  Article  Google Scholar 

  16. 16.

    Fürstenberger G, Krieg P, Müller-Decker K, Habenicht A. What are cyclooxygenases and lipoxygenases doing in the driver’s seat of carcinogenesis? Int J Cancer. 2006;119:2247–54.

    PubMed  Article  CAS  Google Scholar 

  17. 17.

    Shappell SB, Boeglin WE, Olson SJ, Kasper S, Brash AR. 15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. Am J Pathol. 1999;155:235–45.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  18. 18.

    Gohara A, Eltaki N, Sabry D, Murtagh D, Jankun J, Selman SH, Skrzypczak-Jankun E. Human 5, 12-and 15-lipoxygenase-1 coexist in kidney but show opposite trends and their balance changes in cancer. Oncol Rep. 2012;28:1275–82.

    PubMed  Article  Google Scholar 

  19. 19.

    Nixon JB, Kim KS, Lamb PW, Bottone FG, Eling TE. 15-Lipoxygenase-1 has anti-tumorigenic effects in colorectal cancer. Prostaglandins Leukot Essent Fatty Acids. 2004;70:7–15.

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Shureiqi I, Wu Y, Chen D, Yang XL, Guan B, Morris JS, Yang P, Newman RA, Broaddus R, Hamilton SR, Lynch P, Levin B, Fischer SM, Lippman SM. The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. Cancer Res. 2005;65:11486–92.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  21. 21.

    Yuan H, Li M-Y, Ma LT, Hsin MK, Mok TS, Underwood MJ, Chen GC. 15-Lipoxygenases and its metabolites 15 (S)-HETE and 13 (S)-HODE in the development of non-small cell lung cancer. Thorax. 2010;65:321–6.

    PubMed  Article  Google Scholar 

  22. 22.

    Shureiqi I, Xu X, Chen D, Lotan R, Morris JS, Fischer SM, Lippman SM. Nonsteroidal anti-inflammatory drugs induce apoptosis in esophageal cancer cells by restoring 15-lipoxygenase-1 expression. Cancer Res. 2001;61:4879–84.

    CAS  PubMed  Google Scholar 

  23. 23.

    Philips BJ, Dhir R, Hutzley J, Sen M, Kelavkar UP. Polyunsaturated fatty acid metabolizing 15-lipoxygenase-1 (15-LO-1) expression in normal and tumorigenic human bladder tissues. Appl Immunohistochem Mol Morphol. 2008;16:159–64.

    CAS  PubMed  Article  Google Scholar 

  24. 24.

    Middleton MK, Zukas AM, Rubinstein T, Jacob M, Zhu P, Zhao L, Blair I, Puré E. Identification of 12/15-lipoxygenase as a suppressor of myeloproliferative disease. J Exp Med. 2006;203:2529–40.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  25. 25.

    Snodgrass RG, Brüne B. Regulation and functions of 15-lipoxygenases in human macrophages. Front Pharmacol. 2019;10:719.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  26. 26.

    Jack GS, Brash AR, Olson SJ, Manning S, Coffey CS, Smith JA, Shappell SB. Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia. Hum Pathol. 2000;31:1146–54.

    CAS  PubMed  Article  Google Scholar 

  27. 27.

    Gonzalez AL, Roberts RL, Massion PP, Olson SJ, Shyr Y, Shappell SB. 15-Lipoxygenase-2 expression in benign and neoplastic lung: an immunohistochemical study and correlation with tumor grade and proliferation. Hum Pathol. 2004;35:840–9.

    CAS  PubMed  Article  Google Scholar 

  28. 28.

    Xu XC, Shappell SB, Liang Z, Song S, Menter D, Subbarayan V, Iyengar S, Tang DG, Lippman SM. Reduced 15S-lipoxygenase-2 expression in esophageal cancer specimens and cells and upregulation in vitro by the cyclooxygenase-2 inhibitor, NS398. Neoplasia. 2003;5:121–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  29. 29.

    Brash AR, Boeglin WE, Chang MS. Discovery of a second 15S-lipoxygenase in humans. Proc Natl Acad Sci USA. 1997;94:6148–52.

    CAS  PubMed  Article  Google Scholar 

  30. 30.

    Ghosh J, Myers CE. Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochem Biophys Res Commun. 1997;235:418–23.

    CAS  PubMed  Article  Google Scholar 

  31. 31.

    Pidgeon GP, Kandouz M, Meram A, Honn KV. Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. Cancer Res. 2002;62:2721–7.

    CAS  PubMed  Google Scholar 

  32. 32.

    Matsuyama M, Yoshimura R, Mitsuhashi M, Hase T, Tsuchida K, Takemoto Y, Kawahito Y, Sano H, Nakatani T. Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors. Int J Oncol. 2004;24:821–7.

    CAS  PubMed  Google Scholar 

  33. 33.

    Hosseinymehr M, Matin MM, Sadeghian H, Bahrami AR, Kaseb-Mojaver N. 8-Farnesyloxycoumarin induces apoptosis in PC-3 prostate cancer cells by inhibition of 15-lipoxygenase-1 enzymatic activity. Anticancer Drugs. 2016;27:854–62.

    CAS  PubMed  Article  Google Scholar 

  34. 34.

    Orafaie A, Sadeghian H, Bahrami AR, Saboormaleki S, Matin MM. 5-farnesyloxycoumarin: a potent 15-LOX-1 inhibitor, prevents prostate cancer cell growth. Med Chem Res. 2017;26:227–34.

    CAS  Article  Google Scholar 

  35. 35.

    Saboormaleki S, Sadeghian H, Bahrami AR, Orafaie A, Matin MM. 7-farnesyloxycoumarin exerts anti-cancer effects on a prostate cancer cell line by 15-LOX-1 inhibition. Arch Iran Med. 2018;21:251–9.

    PubMed  Google Scholar 

  36. 36.

    Goftari SN, Sadeghian H, Bahrami AR, Maleki F, Matin MM. Stylosin and some of its synthetic derivatives induce apoptosis in prostate cancer cells as 15-lipoxygenase enzyme inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2019;392:1491–502.

    CAS  PubMed  Article  Google Scholar 

  37. 37.

    Eleftheriadis N, Neochoritis CG, Leus NG, van der Wouden PE, Domling A, Dekker FJ. Rational development of a potent 15-lipoxygenase-1 inhibitor with in vitro and ex vivo anti-inflammatory properties. J Med Chem. 2015;58:7850–62.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  38. 38.

    ElBordiny HS, El-Miligy MM, Kassab SE, Daabees H, Ali WAM, El-Hawash SAM. Design, synthesis, biological evaluation and docking studies of new 3-(4, 5-dihydro-1H-pyrazol/isoxazol-5-yl)-2-phenyl-1H-indole derivatives as potent antioxidants and 15-lipoxygenase inhibitors. Eur J Med Chem. 2018;145:594–605.

    CAS  PubMed  Article  Google Scholar 

  39. 39.

    Guo H, Verhoek IC, Prins GG, van der Vlag R, van der Wouden PE, van Merkerk R, et al. Novel 15-lipoxygenase-1 inhibitor protects macrophages from lipopolysaccharide-induced cytotoxicity. J Med Chem. 2019;62:4624–37.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  40. 40.

    Sarveswaran S, Thamilselvan V, Brodie C, Ghosh J. Inhibition of 5-lipoxygenase triggers apoptosis in prostate cancer cells via down-regulation of protein kinase C-epsilon. Biochim Biophys Acta. 2011;1813:2108–17.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  41. 41.

    Sarveswaran S, Chakraborty D, Chitale D, Sears R, Ghosh J. Inhibition of 5-lipoxygenase selectively triggers disruption of c-Myc signaling in prostate cancer cells. J Biol Chem. 2015;290:4994–5006.

    CAS  PubMed  Article  Google Scholar 

  42. 42.

    Lövey J, Nie D, Tóvári J, Kenessey I, Kandouz M, Tímár J, et al. Selective 12-lipoxygenase inhibition potentiates the effect of radiation on human prostate cancer cells in vitro and in vivo. Magy Onkol. 2014;58:211–8.

    PubMed  Google Scholar 

  43. 43.

    Lövey J, Nie D, Tóvári J, Kenessey I, Tímár J, Kandouz M, et al. Radiosensitivity of human prostate cancer cells can be modulated by inhibition of 12-lipoxygenase. Cancer Lett. 2013;335:495–501.

    PubMed  Article  CAS  Google Scholar 

  44. 44.

    Shah R, Shchepinov MS, Pratt DA. Resolving the role of lipoxygenases in the initiation and execution of ferroptosis. ACS Cent Sci. 2018;4:387–96.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  45. 45.

    Yang X, Liu J, Wang C, Cheng KK, Xu H, Li Q, et al. miR-18a promotes glioblastoma development by down-regulating ALOXE3-mediated ferroptotic and anti-migration activities. Oncogenesis. 2021;10:15.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  46. 46.

    Bakavoli M, Nikpour M, Rahimizadeh M, Saberi M, Sadeghian H. Design and synthesis of pyrimido [4, 5-b][1, 4] benzothiazine derivatives, as potent 15-lipoxygenase inhibitors. Bioorg Med Chem. 2007;15:2120–6.

    CAS  PubMed  Article  Google Scholar 

  47. 47.

    Nikpour M, Mousavian M, Davoodnejad M, Alimardani M, Sadeghian H. Synthesis of new series of pyrimido [4, 5-b][1, 4] benzothiazines as 15-lipoxygenase inhibitors and study of their inhibitory mechanism. Med Chem Res. 2013;22:5036–43.

    CAS  Article  Google Scholar 

  48. 48.

    Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55–63.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  49. 49.

    Maleki EH, Bahrami AR, Sadeghian H, Matin MM. Discovering the structure–activity relationships of different O-prenylated coumarin derivatives as effective anticancer agents in human cervical cancer cells. Toxicol In Vitro. 2020;63:104745.

    CAS  PubMed  Article  Google Scholar 

  50. 50.

    Chen D, Eyupoglu IY, Savaskan N. Ferroptosis and cell death analysis by flow cytometry. Cell Viability Assays: Springer; 2017. p. 71–7.

    Google Scholar 

  51. 51.

    Jivrajani M, Shaikh MV, Shrivastava N, Nivsarkar M. An improved and versatile immunosuppression protocol for the development of tumor xenograft in mice. Anticancer Res. 2014;34:7177–83.

    PubMed  Google Scholar 

  52. 52.

    Li Y, Duo Y, Zhai P, He L, Zhong K, Zhang Y, et al. Dual targeting delivery of miR-328 by functionalized mesoporous silica nanoparticles for colorectal cancer therapy. Nanomedicine. 2018;13:1753–72.

    CAS  PubMed  Google Scholar 

  53. 53.

    Nurgali K, Jagoe RT, Abalo R. Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae? Front Pharmacol. 2018;9:245.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  54. 54.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.

    PubMed  PubMed Central  Article  Google Scholar 

  55. 55.

    Mashima R, Okuyama T. The role of lipoxygenases in pathophysiology; new insights and future perspectives. Redox Biol. 2015;6:297–310.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  56. 56.

    Chen B, Tsui S, Boeglin WE, Douglas RS, Brash AR, Smith TJ. Interleukin-4 induces 15-lipoxygenase-1 expression in human orbital fibroblasts from patients with graves disease: evidence for anatomic site-selective actions of Th2 cytokines. J Biol Chem. 2006;281:18296–306.

    CAS  PubMed  Article  Google Scholar 

  57. 57.

    Simard-Bisson C, Parent LA, Moulin VJ, Fruteau de Laclos B. Characterization of epidermal lipoxygenase expression in normal human skin and tissue-engineered skin substitutes. J Histochem Cytochem. 2018;66:813–24.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  58. 58.

    Kelavkar U, Glasgow W, Eling TE. The effect of 15-lipoxygenase-1 expression on cancer cells. Curr Urol Rep. 2002;3:207–14.

    PubMed  Article  Google Scholar 

  59. 59.

    DiGiovanni J, Kiguchi K, Frijhoff A, Wilker E, Bol DK, Beltrán L, et al. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci USA. 2000;97:3455–60.

    CAS  PubMed  Article  Google Scholar 

  60. 60.

    Maccarrone M, Melino G, Finazzi-Agro A. Lipoxygenases and their involvement in programmed cell death. Cell Death Differ. 2001;8:776–84.

    CAS  PubMed  Article  Google Scholar 

  61. 61.

    Kuhn H, Banthiya S, Van Leyen K. Mammalian lipoxygenases and their biological relevance. Biochim Biophys Acta. 2015;1851:308–30.

    CAS  PubMed  Article  Google Scholar 

  62. 62.

    Tousignant KD, Rockstroh A, Poad BL, Talebi A, Young RS, Fard AT, et al. Therapy-induced lipid uptake and remodeling underpin ferroptosis hypersensitivity in prostate cancer. Cancer Metab. 2020;8:11.

    PubMed  PubMed Central  Article  Google Scholar 

  63. 63.

    Yang WS, Kim KJ, Gaschler MM, Patel M, Shchepinov MS, Stockwell BR. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci USA. 2016;113:4966–75.

    Article  CAS  Google Scholar 

  64. 64.

    Diehl R, Ferrara F, Müller C, Dreyer AY, McLeod DD, Fricke S, et al. Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches. Cell Mol Immunol. 2017;14:146–79.

    CAS  PubMed  Article  Google Scholar 

  65. 65.

    Okada S, Vaeteewoottacharn K, Kariya R. Application of highly immunocompromised mice for the establishment of patient-derived xenograft (PDX) models. Cells. 2019;8:889–99.

    CAS  PubMed Central  Article  PubMed  Google Scholar 

  66. 66.

    Szadvari I, Krizanova O, Babula P. Athymic nude mice as an experimental model for cancer treatment. Physiol Res. 2016;65:441–53.

    Article  Google Scholar 

  67. 67.

    Cunha AM, Nascimento FS, Amaral JC, Konig S, Takiya CM, Neto VM, et al. A murine model of xenotransplantation of human glioblastoma with imunosupression by orogastric cyclosporin. Arq Neuropsiquiatr. 2011;69:112–7.

    PubMed  Article  Google Scholar 

  68. 68.

    Du X, Bai Z, Zhang J, Liu L, Han Y, Wang Z, et al. Prolonged survival of human hepatocarcinoma cells in the liver of newborn C57BL/6 mice and resulting cellular xenorejection, especially the activation of hepatic natural killer T cells. Pathobiology. 2010;77:115–28.

    CAS  PubMed  Article  Google Scholar 

  69. 69.

    Rose A, Ilett K, O’Donoghue H, Hackett L, Penhale W, Manning L, et al. Cyclosporin immunosuppression of sheep: pharmacokinetics and allograft survival. Vet Immunol Immunopathol. 2001;81:23–36.

    CAS  PubMed  Article  Google Scholar 

Download references


The authors would like to thank Dr. Noroozpour Laboratory for their great technical help with tissue processing. We sincerely thank Dr. Haniyeh Shaterzade for her excellent histological analysis and also Miss. Tayebe Moghaddam for her kind technical assistance in animal studies.


This work was supported by the Ferdowsi University of Mashhad, Grant Numbers: 51537 and 51720.

Author information




SI and AKMAM conducted the methodology and inferences, carried out the statistical analyses, and wrote the manuscript. ARB had financial support and proofread the manuscript. HS carried out the chemical synthesis and performed lipoxygenase inhibitory assessment. MMM conceived the original idea and designed the study, had financial support, analyzed the results, and wrote the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Maryam M. Matin.

Ethics declarations

Ethics approval and consent to participate

The animal experiments were approved and conducted in accordance with Animal Ethics Committee of Ferdowsi University of Mashhad (IR.UM.REC.1399.001).

Consent for publication

Not applicable for this section.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Iranpour, S., Al-Mosawi, A.K.M., Bahrami, A.R. et al. Investigating the effects of two novel 4-MMPB analogs as potent lipoxygenase inhibitors for prostate cancer treatment. J of Biol Res-Thessaloniki 28, 10 (2021).

Download citation


  • Prostate cancer
  • Lipoxygenases
  • Chemotherapy
  • Targeted therapy